CTMX
NASDAQ · Biotechnology
Cytomx Therapeutics Inc
$4.24
-0.22 (-4.93%)
Financial Highlights (FY 2026)
Revenue
275.61M
Net Income
63.61M
Gross Margin
—
Profit Margin
23.1%
Rev Growth
+54.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 45.0% | 45.0% |
| Operating Margin | 18.1% | 16.3% | 14.3% | 15.7% |
| Profit Margin | 23.1% | 21.9% | 12.8% | 9.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 275.61M | 178.16M | 145.29M | 120.96M |
| Gross Profit | — | — | 65.37M | 54.42M |
| Operating Income | 49.89M | 29.02M | 20.81M | 19.03M |
| Net Income | 63.61M | 37.01M | 18.60M | 11.33M |
| Gross Margin | — | — | 45.0% | 45.0% |
| Operating Margin | 18.1% | 16.3% | 14.3% | 15.7% |
| Profit Margin | 23.1% | 21.9% | 12.8% | 9.4% |
| Rev Growth | +54.7% | +54.7% | +5.8% | -7.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 261.90M | 281.15M |
| Total Equity | — | — | 637.36M | 662.84M |
| D/E Ratio | — | — | 0.41 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 53.04M | 32.57M | 25.56M | 23.91M |
| Free Cash Flow | — | — | 18.27M | 13.74M |